NCT00652782View on ClinicalTrials.gov

Effects of MK7418 on Diuresis and Renal Function in Congestive Heart Failure Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

August 31, 2005

Conditions
Congestive Heart FailureRenal Impairment
Interventions
DRUG

rolofyline

rolofyline 2.5 mg IV QD; 15 mg IV QD; 30 mg IV QD; 60 mg IV QD; 3 days

DRUG

Comparator Placebo (unspecified)

Matching placebo for rolofyline IV QD; 3 days

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT00652782 - Effects of MK7418 on Diuresis and Renal Function in Congestive Heart Failure Patients | Biotech Hunter | Biotech Hunter